注意力不足過動症市場機會、成長動力、產業趨勢分析與預測 2024 - 2032

Attention Deficit Hyperactivity Disorder Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

出版日期: 2024年11月04日 | 出版商:

Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球注意力不足過動症市場估值達到 158 億美元，預計 2024 年至 2032 年複合年成長率將超過 5.1%。開發創新療法。對過動症的認知和理解不斷提高也是促成因素，導致對增強診斷和治療方案的需求更大。

ADHD 是一種神經發育障礙，其症狀包括注意力不集中、過動和衝動，影響兒童和成人。 ADHD 市場涵蓋診斷、治療和管理策略，提供藥物治療、行為介入、診斷工具和支援服務，以改善各年齡層患者的治療結果。治療選擇多種多樣，包括藥物和非藥物方法，其中主要解決方案是興奮劑和非興奮劑藥物。

在ADHD 藥物市場中，興奮劑佔銷售額的大部分，到2023 年價值將達到112 億美元。衝動控制。雖然興奮劑因其快速有效而成為過動症治療的基礎部分，但個別化治療計劃和長期監測對於控制潛在副作用和確保持續效益至關重要。非刺激性選擇雖然通常效果較差，但為尋求不同方法的患者提供了替代方案。

市場範圍
開始年份	2023年
預測年份	2024-2032
起始值	158 億美元
預測值	246 億美元
複合年成長率	5.1%

該市場按年齡層進行細分，到 2023 年，兒童將佔 67.1% 的很大佔有率。介入措施可能包括行為治療、教育支持和必要時的藥物治療。

從性別來看，男性主導市場，由於過動和衝動行為更明顯，男性在診斷中佔很大比例。這種較高的盛行率刺激了有針對性的治療方法，以解決男性在教育和社會環境中經常面臨的獨特挑戰。

在劑型中，片劑佔據最大的市場佔有率，到2023年將達到92億美元。零售藥局在分銷多動症藥物方面發揮關鍵作用，為市場貢獻了 93 億美元，其好處包括便利性、定期處方補充和保險管理支援。

在美國，ADHD 市場預計將以5.1% 的複合年成長率成長，到2032 年將達到102 億美元。這種成長是由高認知度、治療保險覆蓋以及數位治療選擇創新推動的，從而增加了市場機會。

The Global Attention Deficit Hyperactivity Disorder Market reached a valuation of USD 15.8 billion in 2023 and is anticipated to expand at a CAGR of over 5.1% from 2024 to 2032. This growth is primarily driven by increasing ADHD diagnoses, advancements in diagnostic tools, and the continuous development of innovative treatments. Rising awareness and understanding of ADHD are also contributing factors, leading to greater demand for enhanced diagnosis and treatment options.

ADHD, a neurodevelopmental disorder characterized by symptoms such as inattention, hyperactivity, and impulsivity, affects both children and adults. The ADHD market covers diagnosis, treatment, and management strategies, offering pharmaceutical therapies, behavioral interventions, diagnostic tools, and support services to improve patient outcomes across age groups. Treatment options are diverse, encompassing both pharmacological and non-pharmacological approaches, with stimulant and non-stimulant medications among the primary solutions.

In the ADHD drug market, stimulants account for the majority of sales, valued at USD 11.2 billion in 2023. These medications work by increasing norepinephrine and dopamine levels in the brain, helping improve attention, focus, and impulse control. While stimulants have become a foundational part of ADHD treatment due to their rapid effectiveness, individualized treatment plans and long-term monitoring are essential to manage potential side effects and ensure sustained benefits. Non-stimulant options, though generally less effective, provide alternatives for patients seeking different approaches.

Market Scope
Start Year	2023
Forecast Year	2024-2032
Start Value	$15.8 Billion
Forecast Value	$24.6 Billion
CAGR	5.1%

The market is segmented by age group, with children representing a substantial share of 67.1% in 2023. Early diagnosis and tailored interventions are vital for children with ADHD, helping them address challenges that impact their academic and social development. Interventions may include behavioral therapy, educational support, and medication as needed.

Gender-wise, males lead the market, with a significant portion of diagnoses due to the more visible nature of hyperactive and impulsive behaviors. This higher prevalence has spurred targeted treatment approaches to address the unique challenges males often face in educational and social environments.

Among dosage forms, tablets hold the largest market share, reaching USD 9.2 billion in 2023. Tablets, including immediate-release and extended-release formulations, allow flexible dosing for both children and adults. Retail pharmacies play a critical role in distributing ADHD medications, contributing USD 9.3 billion to the market, with benefits including convenience, regular prescription refills, and insurance management support.

In the U.S., the ADHD market is expected to grow at a 5.1% CAGR, reaching USD 10.2 billion by 2032. This growth is driven by high awareness, insurance coverage for treatments, and innovations in digital therapeutic options, enhancing market opportunities.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing ADHD diagnosis rates
  - 3.2.1.2 Advancements in pharmaceutical treatments
  - 3.2.1.3 Increased awareness and education
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of ADHD medications
  - 3.2.2.2 Side effects and concerns with medications
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates & Forecast, By Drug Type, 2021-2032 ($ Mn)

5.1 Key trends
5.2 Stimulants
- 5.2.1 Amphetamine
- 5.2.2 Methylphenidate
- 5.2.3 Lisdexamfetamine
- 5.2.4 Dexmethylphenidate
- 5.2.5 Dextroamphetamine
5.3 Non-stimulants
- 5.3.1 Atomoxetine
- 5.3.2 Guanfacine
- 5.3.3 Clonidine
- 5.3.4 Other non-stimulants

Chapter 6 Market Estimates & Forecast, By Age Group, 2021-2032 ($ Mn)

6.1 Key trends
6.2 Children
6.3 Adults

Chapter 7 Market Estimates & Forecast, By Gender, 2021-2032 ($ Mn)

7.1 Key trends
7.2 Male
7.3 Female

Chapter 8 Market Estimates & Forecast, By Dosage Form, 2021-2032 ($ Mn)

8.1 Key trends
8.2 Tablets
8.3 Capsules
8.4 Other dosage forms

Chapter 9 Market Estimates & Forecast, By Distribution Channel, 2021-2032 ($ Mn)

9.1 Key trends
9.2 Retail pharmacy
9.3 Hospital pharmacy
9.4 Online pharmacy

Chapter 10 Market Estimates & Forecast, By Region, 2021-2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
10.6 MEA
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE